Search results
I’m an Economist: Here Are My Predictions for the Job Market If Trump Wins the Election
GOBankingRates via Yahoo Finance· 4 hours agoThe 2024 election is heating up and if former President Donald Trump manages to retake the White...
Inside a 'foldable' apartment that allows a family of 3 to live comfortably in 400 square feet
Business Insider via Yahoo News· 9 hours agoUnwilling to chance the New York City market — in which homes usually just get more expensive — the...
Medical Breakthroughs: Using induction therapy to treat tongue cancer
KRGV Rio Grande Valley· 4 hours agoDoctors are shining a light on tongue cancer. Chemo, radiation and surgery take a toll on the body...
'Scotland must work on being more clinical' - Christie
BBC via Yahoo Sports· 1 day agoScotland must work on being "a bit more clinical" for Euro 2024, says midfielder Ryan Christie....
Study Identifies Genetic Variant as a Clear Cause of Alzheimer's—Does This Mean You Should Get...
Health via Yahoo News· 5 hours agoNew research suggests that having two copies of a gene variant could be an underlying cause—not just...
Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
Zacks via Yahoo Finance· 8 hours agoOcugen’s cash balance of $26.4 million is a major cause of concern as it will need funds to run...
Experts report drug-resistant fungi linked to tough-to-treat jock itch, athlete's foot
UPI· 4 hours agoThe two fungi reported are among a group that cause skin rashes of the face, limbs, groin and feet,...
Gilead progresses subject enrolment in HIV prevention trials
Clinical Trials Arena via Yahoo Finance· 12 hours agoThe first participants for PURPOSE 3/HPTN-102 were enrolled at a site at the University of...
MDMA drug for PTSD panned by FDA advisers citing trial flaws - The Boston Globe
The Boston Globe· 1 hour agoThe psychedelic drug MDMA failed to get backing from US regulatory advisers to treat a form of...
U.S. health experts vote against MDMA as treatment for PTSD
The Raw Story· 9 hours agoCalifornia-based Lykos Therapeutics has based its request for regulatory approval on two clinical...